null

The query refers to the enzymatic bridge in the intrinsic coagulation pathway, where activated Factor IX (Factor IXa) and its cofactor, Factor VIIIa, together convert Factor X to its active form, Factor Xa, on phospholipid surfaces such as activated platelets[1][3][7][9]. This step—often called the intrinsic tenase complex—is essential for the generation of thrombin and the eventual formation of a stable fibrin clot. Factor IXa is a serine protease that catalyzes the activation of Factor X; dysfunction or deficiency in either results in bleeding disorders (such as hemophilia B, due to Factor IX deficiency)[1][3][9]. This pathway is not a discrete drug target itself but involves multiple targetable proteins (e.g., Factor IX, Factor X, and their active forms), many of which are clinically relevant for hereditary and acquired coagulation deficiencies, and are targets for anticoagulant therapies[5]. Drugs may inhibit, mimic, or supplement components of this pathway to either promote or inhibit clotting, depending on the clinical need.

Other names

Intrinsic tenase complexFactor IXa–Factor X interactionTenase complex (intrinsic)

Inhibit interaction between Factor IXa and Factor X to prevent coagulation - Supplement Factor IX or X to restore pathway function - Directly inhibit Factor X or Xa to prevent thrombin generation